查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840759

C反应蛋白检测市场按产品类型、技术、最终用户、应用、检测类型和样品类型划分－2025-2032年全球预测

C-Reactive Protein Testing Market by Product, Technology, End User, Application, Test Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，C 反应蛋白检测市场将成长至 44.3 亿美元，复合年增长率为 12.77%。

关键市场统计数据
基准年 2024 16.9亿美元
预计年份：2025年 19.1亿美元
预测年份 2032 44.3亿美元
复合年增长率 (%) 12.77%

了解C反应蛋白检测在急诊、慢性病管理和人群健康管理的临床重要性和不断发展的效用

C反应蛋白（CRP）检测处于临床诊断和人群健康管理的关键交汇点，它既是全身发炎的快速生化指标，也是整体急性和慢性疾病的替代标记。在临床实践中，CRP检测结果可用于指导感染疾病和发炎性疾病的诊断路径，指南自体免疫疾病的治疗监测，并在采用高敏感性CRP（hs-CRP）检测方法时用于心血管风险分层。检测方式从集中式平台向分散式即时检测（POC​​）解决方案的演变，扩大了临床应用范围，并拓展了CRP结果影响决策的适用场景。

技术进步和医疗模式的变革正在显着改变临床医生对检测週转时间、分析灵敏度以及与医疗资讯系统无缝整合等方面的期望。因此，采购团队和实验室管理人员在评估CRP检测时，不仅要考虑其分析性能，还要考虑其与工作流程的兼容性、总体拥有成本以及与电子健康记录和实验室资讯系统的互通性。随着CRP临床应用范围的扩大，医院、门诊和研究机构的相关人员正在重新调整如何将CRP资料纳入诊断演算法和慢性病管理路径。

快速分散化、检测灵敏度提高和资讯服务整合如何重新定义CRP诊断在临床护理中的策略价值

由于技术创新、临床指南的不断更新以及诊断的去中心化，CRP检测领域正在发生显着变化。即时检测（POC​​）分析仪正从基本的定性输出转向快速提供定量、具有临床意义的CRP值，从而支持在门诊和急诊环境中进行现场临床决策。同时，实验室分析仪的通量和自动化程度也不断提高，试剂开发人员也在改进检测化学方法，以提高高敏感性CRP（hs-CRP）应用（尤其是与心血管风险评估相关的应用）的灵敏度和特异性。

随着相关人员要求标准化报告、统一的品管以及将CRP结果整合到更广泛的临床决策支援工具中，资料管理和咨询服务的重要性日益凸显。此外，将发炎标记与代谢、肿瘤和感染疾病病理联繫起来的多学科研究，正在创造超越传统急诊诊断的全新临床应用场景。简而言之，市场正从将CRP检测视为商品的观念转向以价值主导的模式，在这种模式下，分析性能、工作流程整合和实际应用价值决定了检测的普及程度。

评估2025年美国关税对CRP测试采购和製造策略的累积营运和供应链影响

近期美国针对进口商品实施的关税措施（有效期至2025年）造成了复杂的贸易影响，波及CRP检测组件和成品设备的供应链及筹资策略。依赖跨境采购仪器、试剂或关键耗材的製造商正面临到岸成本变化和前置作业时间延长的困境，促使许多製造商重新评估其供应链弹性措施。为此，一些上游供应商正在加速推进双通路采购策略并增加库存缓衝以缓解供应中断，而下游实验室客户则在调整采购计画以保障临床工作的连续性。

关税调整不仅影响直接的成本和物流，也影响更长期的策略决策，例如优化区域製造地和试剂在地化生产，以降低贸易波动带来的风险。这种转变也促使诊断试剂生产商与契约製造链的灵活性和供应商的透明度已成为依赖CRP检测的机构的首要考虑因素。

透过对产品、技术、最终用户、应用、检测类型和样本类型进行全面的細項分析，揭示了CRP检测的临床重点和创新路径。

精细化的细分视角揭示了影响产品、技术、最终用户、应用、测试类型和样本类型采购和开发优先顺序的差异化需求驱动因素和营运标准。在产品方面，相关人员对分析仪类别中的实验室分析仪和照护现场仪的评估期望各不相同。实验室分析仪优先考虑通量和自动化，而照护现场分析仪则强调速度、便携性和易用性。试剂和套件分为 CRP套件和 hs-CRP套件，检测敏感度和批间一致性会影响临床效用。软体和服务包括支援品质保证、互通性和纵向资料分析的咨询和资料管理软体。

技术选择——包括酶联免疫吸附试验 (ELISA)、免疫比浊法（包括乳胶增强法和浊度法）以及浊度法——会影响测量精度、试样处理通量以及与现有设备的兼容性。最终用户的需求各不相同。学术研究中心优先考虑检测方法的灵活性和新型标记的验证，而临床机构（包括一级和二级医疗机构）则优先考虑快速週转和易于操作。诊断和监测应用十分广泛，包括心血管疾病（临床医生需要区分心臟疾病和卒中风险）、糖尿病筛检以及各种感染疾病和发炎性疾病，包括自体免疫疾病以及细菌和病毒感染。检测类型的选择区分了半定量方法（例如免疫电泳和侧向层析检测）和具有自动化或手动检测流程的定量方法，每种方法都会影响临床解读和照护现场的适用性。最后，血浆、血清、全血以及EDTA血浆与肝素血浆、毛细血管全血与静脉全血等亚类样本类型的选择，将决定门诊或现场环境下的分析前工作流程和可及性。总而言之，这些细分视角有助于明确在哪些方面进行渐进式创新、有针对性的商业化和营运投资能够带来最大的临床和商业性效益。

主要全球区域的基础设施、监管差异和医疗服务模式将如何决定CRP检测的普及路径和供应策略？

区域动态将对美洲、欧洲、中东和非洲以及亚太地区的CRP检测应用模式、供应链规划、监管合规以及临床偏好产生重大影响。在美洲，整合的医疗保健系统和完善的实验室基础设施（支援集中式高通量检测和即时检测服务）正在推动临床应用。在欧洲、中东和非洲，利害关係人面临管理体制和基础设施差异所带来的挑战。在许多市场，统一的标准与强大的集中式实验室网路并存，同时，尤其是在城市中心，相关人员对分散式诊断的需求也不断增长。

亚太地区拥有强大的大规模生产能力、都市区医疗中心快速的技术应用能力，以及从大型医院系统到社区诊所等多元化的终端使用者群体。这些地区为寻求优化分销、本地化生产和监管策略的製造商和服务供应商带来了独特的挑战和机会。因此，为确保CRP检测解决方案的持续应用，策略性进入和扩张计画必须与各地区的临床实践模式、采购方式以及实验室网路的成熟度相符。

绘製竞争生态系图，展现仪器製造商、试剂专家、软体供应商和即时检测创新者如何齐聚一堂，共同定义 CRP 诊断的价值。

CRP检测生态系统的竞争格局呈现出多元化的特点，既有成熟的诊断试剂製造商，也有专业的试剂开发商、软体和资讯服务提供商，以及敏捷的即时检测（POC​​）创新者，所有这些参与者都在影响着产品的可及性、性能基准化分析和服务模式。领先的仪器製造商正在扩展平台互通性，以适应更广泛的检测化学方法，而试剂专家则致力于提高检测稳定性并降低分析前变异性。同时，软体供应商和顾问公司正在增强资料管理能力，以提供自动化品管、趋势分析以及与电子健康记录的整合。

仪器製造商与第三方试剂供应商之间的伙伴关係仍然普遍，而与契约製造製造商的策略联盟也在不断增加，以支持灵活的生产和本地化供应。新参与企业正透过即时检测外形规格、简化的非实验室负责人操作流程以及包含远端连接和效能监控的配套服务来脱颖而出。对于采购人员和决策者而言，选择供应商越来越依赖临床效能、法规遵循、售后支援以及提供端到端解决方案的能力，从而降低实施风险和营运复杂性。

诊断试剂生产商和医疗保健提供者可采取的切实可行的策略重点，以加快 CRP 检测的效能、普及性和供应弹性。

寻求巩固市场地位和提升临床影响力的产业领导者应优先考虑平衡创新、供应链韧性和互通性的工作。首先，投资提高高敏C反应蛋白（hs-CRP）的敏感性和可重复性，尤其能够满足心血管风险评估和发炎性疾病监测方面尚未满足的临床需求。其次，扩展可与实验室资讯系统整合的模组化照护现场平台，将有助于在门诊和急诊环境中更广泛地应用，从而在就诊时即可进行临床决策并优化诊疗路径。

此外，企业应透过发展区域製造能力或与国内委託製造製造商合作来实现供应链多元化，从而降低贸易波动带来的风险。与临床网络和研究机构建立策略联盟可以加速真实世界证据的生成，并支持指南的发展。最后，将强大的资料管理、远端监测和上市后监控服务整合到产品中，可以为客户提供可衡量的品质保证和长期价值，从而增强商业性差异化和客户维繫。

一种透明的、多来源的调查方法，结合了相关人员访谈、临床检验证据和技术性能评估，能够提供可操作的见解。

本执行摘要的研究基础包括对主要相关人员、采购负责人、医院临床医生、照护现场专案经理和检测方法开发科学家进行讨论，以了解实际运作中的限制因素和临床决策驱动因素。二级资讯来源包括方法学综述和检测方法验证研究，以评估酵素连结免疫吸附试验 (ELISA)、免疫比浊法和浊度法等分析方法之间的权衡取舍。

资料整合优先考虑方法学的透明度，并着重于检测验证参数、重复性指标和样本类型可比较性。品质保证评估检视了监管许可、批间一致性记录以及上市后绩效报告（如有）。分析框架将定性见解与技术性能特征相结合，从而为产品开发、采购和临床实施策略提供切实可行的建议。在整个过程中，我们始终关注分析前变数和工作流程整合，因为我们认识到它们对临床效用和操作推广有显着影响。

最后总结如何透过调整检测效能、工作流程整合和供应灵活性，最大限度地提高 CRP 检测的临床和营运价值。

总之，C反应蛋白检测在急诊、慢性病管理和研究中具有重要的临床意义，随着诊断模式向快速、分散和数据整合的医疗模式转变，其策略重要性日益凸显。仪器性能、检测化学、资讯服务和法规环境之间的相互作用将决定CRP检测在不同医疗机构中的普及速度和有效性。由于供应链因素和贸易措施会影响采购动态，各机构必须优先考虑灵活性、供应商透明度和本地化供应方案，以维持临床服务的连续性。

展望未来，最具影响力的机会将出现在分析绩效提升、工作流程无缝整合以及临床疗效显着结合的领域。因此，决策者应将投资与能够带来明确临床价值的应用情境结合，确保与医疗资讯系统的互通性，并优先考虑能够加速真实世界证据产生的合作。如此一来，相关人员便可将CRP检测不仅作为一种检测手段，更作为一种策略性诊断工具，从而支持更佳的病患管理和系统层面的效率提升。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 照护现场CRP检测平台技术的进步使得快速床边发炎监测成为可能。
  • 高敏C反应蛋白的监管核准和标准化工作
  • 将CRP检测与数位健康工具结合，用于个人化心血管风险评估
  • 病患自我护理趋势推动了家用C反应蛋白监测套件的广泛应用。
  • 新兴的多重免疫检测结合了CRP和细胞激素谱，用于全面的发炎分析。
  • 诊断公司与Start-Ups建立策略伙伴关係，共同创新CRP检测技术
  • 随着慢性发炎性疾病盛行率的上升，新兴市场对CRP检测的应用也日益增加。
  • 远端医疗扩展对远距CRP样本采集和虚拟诊断工作流程的影响
  • 微流体和实验室晶片CRP检测系统的进步缩短了检测时间和样本用量。
  • 扩大医疗支付方对高灵敏度CRP检测的报销和政策支持

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. C反应蛋白检测市场（依产品类型划分）

  • 装置
    • 实验室分析设备
    • 照护现场分析仪
  • 试剂和套件
    • CRP套件
    • 高敏C反应蛋白试剂套件
  • 软体和服务
    • 咨询服务
    • 资料管理软体

9. C反应蛋白检测市场（依技术划分）

  • 伊丽莎
  • 免疫比浊法
    • 乳胶加固
    • 浊度计
  • 浊度法

10. C反应蛋白检测市场（依最终用户划分）

  • 学术研究机构
  • 诊所
    • 一级诊所
    • 二级诊所
  • 诊断实验室
    • 医院实验室
    • 独立实验室
  • 医院
    • 综合医院
    • 专科医院

第十一章 C反应蛋白检测市场（依应用领域划分）

  • 癌症
  • 心血管疾病
    • 冠状动脉疾病
    • 中风
  • 糖尿病
  • 感染疾病和发炎性疾病
    • 自体免疫疾病
    • 细菌感染疾病
    • 病毒感染

12. C反应蛋白检测市场（依检测类型划分）

  • 定量
    • 自动化测试
    • 手动测试
  • 半定量
    • 免疫泳
    • 侧向流动试验

13. C反应蛋白检测市场（依样本类型划分）

  • 电浆
    • EDTA血浆
    • 肝素血浆
  • 血清
  • 全血
    • 微血管血
    • 静脉血

14. C反应蛋白检测市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 C反应蛋白检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国 C 反应蛋白检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Diagnostics International AG
    • Abbott Laboratories, Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Ortho Clinical Diagnostics, LLC
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd
Product Code: MRR-A339DAEFABD5

The C-Reactive Protein Testing Market is projected to grow by USD 4.43 billion at a CAGR of 12.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.91 billion
Forecast Year [2032] USD 4.43 billion
CAGR (%) 12.77%

Understanding the clinical centrality and evolving utility of C-reactive protein testing across acute care, chronic disease management, and population health settings

C-reactive protein (CRP) testing occupies a vital intersection between clinical diagnostics and population health management, serving as a rapid biochemical indicator of systemic inflammation and a surrogate marker across a spectrum of acute and chronic conditions. In clinical practice, CRP assays inform diagnostic pathways for infection and inflammatory disorders, guide therapeutic monitoring in autoimmune disease, and contribute to cardiovascular risk stratification when high-sensitivity (hs-CRP) methods are employed. The evolution of testing modalities from centralized laboratory platforms to decentralized point-of-care solutions has expanded both clinical access and the contexts in which CRP results influence decision-making.

Technological advancement and shifting care models are reshaping clinician expectations about turnaround time, analytical sensitivity, and seamless integration with health information systems. Consequently, procurement teams and laboratory managers must evaluate CRP testing not solely on analytical performance but also on workflow compatibility, total cost of ownership, and interoperability with electronic medical records and laboratory information systems. As the clinical applications of CRP broaden, stakeholders across hospitals, outpatient clinics, and research environments are recalibrating how they incorporate CRP data into diagnostic algorithms and chronic disease management pathways.

How rapid decentralization, assay sensitivity improvements, and integrated data services are redefining the strategic value of CRP diagnostics in clinical care

The landscape for CRP testing is undergoing transformative shifts driven by technological innovation, evolving clinical guidelines, and the decentralization of diagnostics. Point-of-care analyzers are moving beyond basic qualitative outputs to provide quantitative, clinically actionable CRP values with rapid turnaround, enabling same-visit clinical decisions in both outpatient and emergency settings. Simultaneously, laboratory analyzers are increasing throughput and automation while reagent developers refine assay chemistries to enhance sensitivity and specificity, especially for hs-CRP applications relevant to cardiovascular risk assessment.

Data management and consulting services are growing in importance as stakeholders demand standardized reporting, quality control harmonization, and integration of CRP results into broader clinical decision support tools. Moreover, cross-disciplinary research linking inflammation markers to metabolic, oncologic, and infectious disease pathways is fueling novel clinical use cases that extend beyond traditional acute care diagnostics. In short, the market is shifting from a commodity perception of CRP assays to a value-driven model where analytical performance, workflow integration, and real-world clinical impact determine adoption.

Assessing the cumulative operational and supply chain consequences of 2025 US tariff measures on CRP testing procurement and manufacturing strategies

Recent tariff actions affecting imports into the United States in 2025 have created a complex overlay of trade-related considerations that influence supply chains and procurement strategies for CRP testing components and finished devices. Manufacturers that rely on cross-border sourcing for instruments, assay reagents, or critical consumables have encountered altered landed costs and extended lead times, prompting many to re-evaluate supply resiliency measures. In response, several upstream suppliers have accelerated dual-sourcing strategies and increased inventory buffers to mitigate disruption, with downstream laboratory customers adjusting procurement cadence to protect clinical continuity.

Beyond immediate cost and logistics effects, tariff-induced adjustments have influenced longer-term strategic decisions, including regional manufacturing footprint optimization and localized reagent production to reduce exposure to trade fluctuations. This shift has also heightened collaboration between diagnostic firms and contract manufacturers that possess domestic capabilities, thereby shortening supply chains and enhancing quality oversight. In parallel, purchasing groups and health systems are pursuing consolidated contracting models to secure more predictable terms and to leverage volume for better pricing stability. Overall, the cumulative impact has been to make supply chain flexibility and supplier transparency top priorities for organizations that rely on CRP testing.

Comprehensive segmentation analysis across product, technology, end user, application, test type, and sample type to illuminate clinical priorities and innovation pathways for CRP testing

A granular segmentation view reveals differentiated demand drivers and operational criteria across product, technology, end user, application, test type, and sample type that shape procurement and development priorities. From a product perspective, stakeholders evaluate laboratory analyzers and point-of-care analyzers under the instruments category with distinct expectations: centralized laboratory analyzers prioritize throughput and automation while point-of-care analyzers emphasize speed, portability, and ease of use. Reagents and kits are divided between CRP kits and hs-CRP kits, where assay sensitivity and lot-to-lot consistency affect clinical utility. Software and services encompass consulting offerings and data management software that support quality assurance, interoperability, and longitudinal data analytics.

Technology choices-whether ELISA, immunoturbidimetric approaches including latex-enhanced or turbidimetric variants, or nephelometry-affect assay precision, sample throughput, and compatibility with existing instrumentation. End-user contexts vary widely: academic and research institutes focus on assay flexibility and novel marker validation while clinics, which include both tier I and tier II facilities, prioritize rapid turnaround and ease of operation; diagnostic laboratories, subdivided into hospital-based and independent labs, balance throughput with assay cost-efficiency; hospitals, whether general or specialized, demand validated workflows and robust quality systems. Applications span diagnostics and monitoring across cancer, cardiovascular disease where clinicians differentiate between coronary heart disease and stroke risk contexts, diabetes screening interactions, and a broad set of infection and inflammatory disorders including autoimmune conditions as well as bacterial and viral infections. Test type considerations distinguish quantitative methods, with automated and manual test pathways, from semi-quantitative approaches such as immunophoresis and lateral flow tests, each informing clinical interpretation and point-of-care suitability. Finally, sample type decisions-between plasma, serum, and whole blood, and their subcategories such as EDTA or heparin plasma and capillary versus venous whole blood-determine pre-analytical workflows and accessibility in ambulatory or field settings. Taken together, these segmentation lenses clarify where incremental innovation, targeted commercialization, and operational investment can yield the greatest clinical and commercial returns.

How regional infrastructure, regulatory diversity, and care delivery models across major global regions determine CRP testing adoption pathways and supply strategies

Regional dynamics exert a profound influence on adoption patterns, supply chain planning, regulatory navigation, and clinical preferences for CRP testing across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical adoption is driven by integrated health systems and widespread laboratory infrastructure that support both centralized high-throughput testing and expansion of point-of-care services; reimbursement frameworks and clinical practice guidelines further shape where hs-CRP assays gain traction. Moving to Europe, Middle East & Africa, stakeholders contend with heterogeneous regulatory regimes and infrastructure variability; in many markets, harmonized standards coexist with pockets of strong centralized laboratory networks and growing demand for decentralized diagnostics, particularly in urban centers.

Asia-Pacific presents a dynamic mix of high-volume manufacturing capability, rapid technology adoption in urban healthcare hubs, and diverse end-user profiles ranging from large hospital systems to community clinics. Collectively, these regions present distinct challenges and opportunities for manufacturers and service providers seeking to optimize distribution, localized manufacturing, and regulatory strategies. Strategic entry or expansion plans should therefore align with each region's clinical practice patterns, procurement norms, and the maturity of laboratory networks to ensure sustainable uptake of CRP testing solutions.

Mapping the competitive ecosystem where instrument makers, reagent specialists, software vendors, and point-of-care innovators converge to define value in CRP diagnostics

Competitive dynamics in the CRP testing ecosystem are characterized by a mix of established diagnostic manufacturers, specialized reagent developers, software and data service providers, and nimble point-of-care innovators that together shape product availability, performance benchmarks, and service models. Leading instrument makers are extending platform interoperability to accommodate a broader range of assay chemistries while reagent specialists focus on improving assay stability and reducing pre-analytical variability. Concurrently, software vendors and consulting firms are enhancing data management capabilities to deliver automated quality control, trend analysis, and integration with electronic health records-functions that increasingly determine the value proposition for clinical laboratories and health systems.

Partnerships between instrumentation companies and third-party reagent suppliers remain common, and strategic alliances with contract manufacturers have increased to support flexible production and regional supply. New entrants are differentiating through point-of-care form factors, simplified workflows for non-laboratory personnel, and bundled service offerings that include remote connectivity and performance monitoring. For purchasers and decision-makers, vendor selection increasingly hinges on demonstrated clinical performance, regulatory compliance, post-market support, and the ability to provide end-to-end solutions that reduce implementation risk and operational complexity.

Actionable strategic priorities for diagnostic manufacturers and healthcare providers to accelerate CRP test performance, adoption, and supply resilience

Industry leaders seeking to strengthen market position and clinical impact should prioritize initiatives that balance innovation, supply resilience, and interoperability. First, investing in assay performance enhancements-particularly for hs-CRP sensitivity and reproducibility-will address unmet clinical needs in cardiovascular risk assessment and inflammatory disease monitoring. Second, expanding modular point-of-care platforms that integrate with laboratory information systems will facilitate broader adoption across outpatient and emergency settings, enabling same-visit clinical decisions and tighter care pathways.

Additionally, companies should diversify supply chains by developing regional manufacturing capabilities or partnering with domestic contract manufacturers to reduce exposure to trade volatility. Strategic collaborations with clinical networks and research institutions can accelerate real-world evidence generation and support guideline inclusion. Finally, embedding robust data management, remote monitoring, and post-market surveillance services into product offerings will provide customers with measurable quality assurance and long-term value, thereby strengthening commercial differentiation and customer retention.

Transparent, multi-source research methodology combining stakeholder interviews, clinical validation evidence, and technology performance assessments to inform actionable insights

The research underpinning this executive summary integrates primary stakeholder interviews, synthesis of peer-reviewed clinical literature, regulatory filings, and a structured assessment of technology performance characteristics. Primary engagement included discussions with clinical laboratory directors, procurement leaders, hospital clinicians, point-of-care program managers, and assay development scientists to capture real-world operational constraints and clinical decision drivers. Secondary sources comprised methodological reviews and assay validation studies to evaluate analytical trade-offs among ELISA, immunoturbidimetric, and nephelometric approaches.

Data synthesis prioritized methodological transparency: inclusion criteria for studies emphasized assay validation parameters, reproducibility metrics, and sample type comparability. Quality assurance assessments evaluated regulatory clearances, documented lot-to-lot consistency, and post-market performance reports when available. The analytical framework triangulated qualitative insights with technical performance characteristics to generate practical recommendations for product development, procurement, and clinical implementation strategies. Throughout, attention was given to pre-analytical variables and workflow integration, recognizing their outsized impact on clinical utility and operational adoption.

Closing synthesis on aligning assay performance, workflow integration, and supply flexibility to maximize clinical and operational value from CRP testing

In conclusion, C-reactive protein testing retains critical clinical relevance across acute care, chronic disease management, and research contexts, and its strategic importance is increasing as diagnostic paradigms shift toward rapid, decentralized, and data-integrated care models. The interplay between instrument capabilities, assay chemistry, data services, and regulatory environments determines how quickly and effectively CRP testing can be adopted in different care settings. As supply chain considerations and trade measures influence procurement dynamics, organizations must emphasize flexibility, vendor transparency, and localized supply options to maintain clinical continuity.

Looking ahead, the most impactful opportunities will arise where analytical performance improvements are coupled with seamless workflow integration and demonstrable clinical outcomes. Decision-makers should therefore align investments with use cases that deliver clear clinical value, ensure interoperability with health information systems, and prioritize collaborations that accelerate real-world evidence generation. By doing so, stakeholders can harness CRP testing not just as a laboratory assay but as a strategic diagnostic tool that supports better patient management and system-level efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in point-of-care CRP testing platforms enabling rapid bedside inflammation monitoring
  • 5.2. Regulatory approvals and standardization efforts for high-sensitivity C-reactive protein assays
  • 5.3. Integration of CRP testing with digital health tools for personalized cardiovascular risk assessment
  • 5.4. Expansion of home-based C-reactive protein monitoring kits driven by patient self-care trends
  • 5.5. Emergence of multiplex immunoassays combining CRP with cytokine panels for comprehensive inflammation profiling
  • 5.6. Strategic collaborations between diagnostics firms and biotech startups to innovate CRP assay technologies
  • 5.7. Growing adoption of CRP testing in emerging markets amid rising prevalence of chronic inflammatory diseases
  • 5.8. Impact of telemedicine expansion on remote CRP sample collection and virtual diagnostic workflows
  • 5.9. Evolution of microfluidic and lab-on-a-chip CRP detection systems reducing assay time and sample volumes
  • 5.10. Increasing reimbursement coverage and policy support for high-sensitivity CRP testing by healthcare payers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. C-Reactive Protein Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Laboratory Analyzers
    • 8.1.2. Point-Of-Care Analyzers
  • 8.2. Reagents & Kits
    • 8.2.1. Crp Kits
    • 8.2.2. Hs-Crp Kits
  • 8.3. Software & Services
    • 8.3.1. Consulting Services
    • 8.3.2. Data Management Software

9. C-Reactive Protein Testing Market, by Technology

  • 9.1. Elisa
  • 9.2. Immunoturbidimetric
    • 9.2.1. Latex Enhanced
    • 9.2.2. Turbidimetric
  • 9.3. Nephelometry

10. C-Reactive Protein Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Clinics
    • 10.2.1. Tier I Clinics
    • 10.2.2. Tier II Clinics
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Hospital-Based Labs
    • 10.3.2. Independent Labs
  • 10.4. Hospitals
    • 10.4.1. General Hospitals
    • 10.4.2. Specialized Hospitals

11. C-Reactive Protein Testing Market, by Application

  • 11.1. Cancer
  • 11.2. Cardiovascular Diseases
    • 11.2.1. Coronary Heart Disease
    • 11.2.2. Stroke
  • 11.3. Diabetes
  • 11.4. Infection & Inflammatory Disorders
    • 11.4.1. Autoimmune Disorders
    • 11.4.2. Bacterial Infections
    • 11.4.3. Viral Infections

12. C-Reactive Protein Testing Market, by Test Type

  • 12.1. Quantitative
    • 12.1.1. Automated Tests
    • 12.1.2. Manual Tests
  • 12.2. Semi-Quantitative
    • 12.2.1. Immunophoresis Tests
    • 12.2.2. Lateral Flow Tests

13. C-Reactive Protein Testing Market, by Sample Type

  • 13.1. Plasma
    • 13.1.1. Edta Plasma
    • 13.1.2. Heparin Plasma
  • 13.2. Serum
  • 13.3. Whole Blood
    • 13.3.1. Capillary Blood
    • 13.3.2. Venous Blood

14. C-Reactive Protein Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. C-Reactive Protein Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. C-Reactive Protein Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Diagnostics International AG
    • 17.3.2. Abbott Laboratories, Inc.
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Danaher Corporation
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. bioMerieux SA
    • 17.3.7. Ortho Clinical Diagnostics, LLC
    • 17.3.8. DiaSorin S.p.A.
    • 17.3.9. Bio-Rad Laboratories, Inc.
    • 17.3.10. Randox Laboratories Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. C-REACTIVE PROTEIN TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. C-REACTIVE PROTEIN TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. C-REACTIVE PROTEIN TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY POINT-OF-CARE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CRP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HS-CRP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOTURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATEX ENHANCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY NEPHELOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER I CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TIER II CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY CORONARY HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY INFECTION & INFLAMMATORY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY AUTOMATED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY MANUAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SEMI-QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY IMMUNOPHORESIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY LATERAL FLOW TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY EDTA PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY HEPARIN PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL C-REACTIVE PROTEIN TESTING MARKET SIZE, BY SE